Cartesian Therapeutics, Inc. (RNAC), a clinical-stage biotechnology company, on Monday announced that it has received written agreement from the U.S. Food and Drug Administration or FDA on the design of its Phase 3 AURORA trial for Descartes-08, an investigational mRNA cell therapy for the treatment of myasthenia gravis or MG.
The Special Protocol Assessment or SPA agreement confirms that the trial design is acceptable to support a future Biologics License Application or BLA for Descartes-08, pending trial results.
The Phase 3 AURORA trial will evaluate Descartes-08 versus a placebo in approximately 100 participants with acetylcholine receptor autoantibody positive MG, using six once-weekly infusions without preconditioning chemotherapy.
The primary endpoint is based on improvements in the MG-Activities of Daily Living or MG-ADL score after four months.
This milestone follows promising Phase 2b results, which showed significant and lasting improvements in MG symptoms.
Descartes-08 was well-tolerated, supporting its use as an outpatient therapy without the need for chemotherapy. Cartesian plans to initiate the Phase 3 trial in the first half of 2025.
Descartes-08 has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation from the FDA for MG and other autoimmune diseases.
Currently, RNAC is trading at $19.17 down by 0.15%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.